J. A. RIDER, M.D.; W. H. PICKETT, M.D.; A. W. HARRISON, M.D.
This content is PDF only. Please click on the PDF icon to access.
Myasthenia gravis, an endocrine or metabolic disease characterized by excessive fatigability of skeletal muscle, eluded all attempts at treatment until Edgeworth1 in 1930 found that ephedrine was beneficial. Then Walker2 in 1935 introduced neostigmine, which has remained the best and most commonly used therapeutic agent to date. Recently Cholinesterase inhibitors have been used with varying promise. Among these have been "DFP," diisopropyl fluorophosphate used by Comroe,3 "HETP," hexaethyltetraphosphate, employed by Westerberg,4 and "TEPP," tetraethylpyrophosphate, first tried clinically by Burgen.5 Surgical approach began in 1913, when Sauerbruch6 employed thymectomy, but it remained for Blalock7 in 1939 to perform the first
RIDER JA, PICKETT WH, HARRISON AW. MYASTHENIA GRAVIS: REPORT OF CASE RECEIVING UNUSUAL DOSAGE OF NEOSTIGMINE1. Ann Intern Med. 1951;35:463–468. doi: 10.7326/0003-4819-35-2-463
Download citation file:
© 2019
Published: Ann Intern Med. 1951;35(2):463-468.
DOI: 10.7326/0003-4819-35-2-463
Neurology.
Results provided by: